Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Baricitinib (Olumiant®)	TA681 - Baricitinib for treating moderate to severe atopic dermatitis
Baricitinib (Olumiant®)	TA466 - Baricitinib for moderate to severe rheumatoid arthritis	Hospital use only
Basiliximab injection		For hospital use only
BCG (OncoTice®) bladder installation
BCG bladder instillation		For hospital use only
Bee and wasp allergen extracts (Phamalgen)	TA246 - Pharmalgen for the treatment of bee and wasp venom allergy	Hospital only
Belatacept powder concentrate for infusion		For hospital use only
Belimumab	TA397 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus	Hospital use only
Bendamustine injection	TA344 - Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia TA118 - Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Benralizumab	TA565 - Benralizumab for treating severe eosinophilic asthma

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.